2017 pharmaceutical giant annual report and blockbuster drug sales statistics

Source: Yaodu headlines 2018-02-08 recently, the 2017 financial statements of major pharmaceutical enterprises were published one after another Based on the top ranking of last year, the published financial statements were summarized (total revenue, year-on-year growth, R & D investment), and the drugs with high sales (> 1.5 billion US dollars or > 1 billion US dollars) On the basis of statistics, revenue and R & D ratio are calculated, and sales in 2017 are ranked In the financial statements, the total revenue of Africa and the U.S dollar is converted into the above data according to the average exchange rate between 2017 and the U.S dollar, all of which are shown by rounding Johnson & Johnson has the largest income, of which Aberdeen has the fastest growth The revenue R & D ratio of Abbott is the largest, because Abbott's non drug sales revenue is relatively large, and Johnson & Johnson also has many other consumer goods businesses to pull, which has the lowest new base That's the ranking so far, and Sanofi, Gilead and GlaxoSmithKline earned a lot in 2016 As of the date of publication, Bayer still has no financial report Last year's revenue was about $50.623 billion According to the growth trend in the first three quarters of 2017, Bayer will undoubtedly be in the top five Sanofi's revenue from January to September last year has reached US $29.3 billion The 2017 financial report will be released in the near future, and the top 10 list is nothing but him GlaxoSmithKline reported revenue of 147.04 pounds last year, while the third quarter reported revenue of 7.843 billion pounds, up 4% year-on-year, so it is estimated that it will not be lower than the top 10 Geely's revenue from January to September last year was only US $19.825 billion, and the 2017 financial report is estimated to be released in March, but now it seems that it has lost the top 10 Last year's top 10 prescription drug sales were Pfizer, Novartis, Roche, Merck, Sanofi, Johnson & Johnson, Gilead, GlaxoSmithKline, Aberdeen and Amgen Pfizer ranks first in prescription drug sales with us $45.906 billion, and now Johnson & Johnson ranks first Thanks to the sales of its specialty drugs such as REMICADE and stellara, as well as the non pharmaceutical business income, Pfizer will definitely be inferior to Roche if it only ranks by prescription drugs Roche's three magic weapons are awesome, and revenue has increased by 5% over the same period, but it still does not compete with Johnson's consumer health care and medical devices Pfizer and Johnson & Johnson are competing in the pharmaceutical business, especially for non metastatic prostate cancer In addition, Takeda's revenue in 2016 was about $16 billion, an increase of 6.9% It is estimated that its 2017 profit will continue to grow, about $17.1 billion There are entyvio ® and takecab ® in the field of tumor, and zafatek in the field of diabetes Although ad has failed, it has reached R & D cooperation with the cutting-edge Denali However, the financial report was released relatively late, and now it is estimated that it will be in the top 20 Among the top ten best-selling drugs, there are five drugs in the field of cancer, and three in the field of immunology The three cancer drugs of Roche, Herceptin, Avastin and mabthera / rituxan, together account for 27.04% of the total sales of the top ten, while EBV Humira, with one enemy and three, accounts for 25.00% of the total sales of the top ten Sanofi's insulin glargine is also the best-selling drug in 2017, but the sales volume in 2017 has not been announced yet In addition, harvoni (sofosbuvir / ledipasvir) and eyla of Bayer are not disclosed The overall trend is in line with the forecast of evaluation Pharma at the beginning of 2017 (top 10, the best selling drug in 2017) In 2018, REMICADE, opdivo, Herceptin, mabthera / rituxan, Avastin, Enbrel, revimid and Humira will continue to sell well In addition, keytruda of mosadon and eylea abacept, Bayer's ophthalmic drug, will continue to sell well Source: official website and SEC Website of each company